In 2016, President Barack Obama appointed Vice President Joe Biden to lead a "Cancer Moonshot" initiative to accelerate and consolidate efforts to prevent, diagnose and treat cancer.
The Cancer Moonshot Task Force delivered its report 1 in October 2016, and laid out its vision to transform cancer research and care, and "achieve a decade's worth of progress in 5 years".
Colorectal Cancer (CRC) was prominently featured in the report: Strategic Goal 4 aims to advance health programs, policies, and outreach to help Americans reduce their cancer risk, strengthen understanding of environmental determinants of cancer, and enhance the cancer screening continuum-concepts which are at the core of CRC prevention. Specifically, the report focuses on the expansion of CRC screening in the US, the removal of insurance barriers, and recognizes the National Colorectal Cancer Roundtable's "80% by 2018" initiative 2 (to increase CRC screening rates of eligible adults to 80 percent by 2018) as a driving force for state-and local-level initiatives to increase CRC screening.
CRC is a quintessential example of a "screenable" disease 3 : It is common and in general has a long latency period, early detection can decrease mortality, accurate screening modalities and effective treatment options are available, resources are available to screen and to provide diagnostic tests in those with positive screening, screening is cost-effective, and modalities to screen are accepted by patients and providers. It should also be reemphasized that a fundamental attribute of CRC, and one which distinguishes it from other cancers for which screening is recommended and widely practiced, is that it is amenable to primary prevention.
Fletcher and colleagues 4 remind us that prevention is "the act of keeping from happening", and outline the levels of prevention based on timing during disease course: primary prevention keeps the disease from occurring at all, by removing its causes and controlling risk factors; secondary prevention detects disease early at the asymptomatic stage and when treatment can halt progression; tertiary prevention is focused on reduction of complications after disease has become clinically evident. Screening for CRC is, to a certain extent, secondary prevention:
CRC-related mortality is related directly to disease stage at diagnosis; thus, early detection identifies at-risk patients before symptoms occur and increases the chances of a favorable outcome. Unlike other cancers though, for which early detection (secondary prevention) is the only option, screening for CRC relies to a great extent on primary prevention, predominantly through the detection and removal of precancerous colorectal polyps. This concept is not new:
in the 1960s, Gilbertsen 5 suggested that CRC could be a preventable malignancy through polypectomy, before the Vogelstein model 6 provided the biologic framework (adenoma to carcinoma sequence with long latency) supporting the rationale for more widespread screening.
CRC screening with current modalities has been shown to decrease cancer occurrence and death, and concrete benefits of screening are discernible at the population level: a recent large
German population-based study 7 showed that cancers detected by screening colonoscopy had a lower stage than those diagnosed by colonoscopy in patients with symptoms; the magnitude of stage shift was comparable to patients undergoing screening by fecal occult blood testing.
Where do we stand globally with regards to CRC incidence and mortality? In the US, there have been significant long-term declines in overall CRC rates since a peak in the mid1980s, and the declines have been more pronounced for those 65 years or older 8 . There has been vigorous debate 9 regarding the mechanisms driving these downward trends, with some attributing the benefit primarily to mass screening, and others to improved risk factors. There is a reasonable rationale for both sides of the argument. The observed declines started before widespread screening for CRC, and the timing of decreased mortality at the population level is not consistent with an effect of screening 9 , because of the significant time lag (up to a decade) between receipt of screening and measurable impact on CRC death rates 10, 11 coupled with the relatively slow uptake of screening in clinical practice 9 . On the other hand, the more recent accelerated declines of proximal colon cancer are more plausibly driven by increased use of screening colonoscopy and polypectomy, and CRC incidence and mortality have increased in persons younger than 50 years, for whom screening is not routinely recommended. Similarly, the "risk factor" hypothesis cannot explain the whole picture. A lot has been written about the nefarious effects of the Western lifestyle, and the associations between obesity, the metabolic syndrome and its components, lack of physical activity, cigarette smoking, and the risk of colorectal neoplasia. Disentangling the effect of these factors on CRC risk at a population level is more complex than that of screening: while screening is a defined event which can be isolated in time, the lifestyle risk factors interact with one another, are influenced by individual predisposing genetic and other factors (such as aspirin/NSAID and calcium use), and exert their effect over many years. In addition, some of these factors would be expected to influence CRC risk in opposite directions; for example, increasing rates of obesity versus decreasing prevalence of cigarette smoking. Screening is likely driving the decline in CRC incidence to a greater extent than that of CRC mortality, because CRC-related deaths are also affected by earlier detection of symptomatic disease, and improvements in cancer therapy. However, ascribing the decreasing CRC rates primarily to screening or improved risk factors oversimplifies the issue, as it is likely that both are contributory, albeit to a different extent depending on time frame.
Outside the US, the CRC landscape is less than encouraging. The GLOBOCAN 2012 data 12 depict wide geographical variation in incidence, with rates varying ten-fold in both sexes worldwide (highest estimated rates in Australia/New Zealand and lowest in Western Africa).
Nearly 55% of the cases occur in more developed regions, while more CRC-related deaths (52% of the total) occur in less developed regions, reflecting the impact of delayed diagnosis and decreased access to modern therapeutic options. Contrary to the US trends, worldwide, 
